open access

Vol 15, No 1 (2019)
Case report
Published online: 2019-04-16
Get Citation

A paraplegic patient with fever and leucocytosis: not always what it seems

Ashley J.R. De Bie, Simon Körver, Erik Kersten, Jérôme M.H. Kisters, Henricus J.E.J. Vrijhof, Jeroen Willems
DOI: 10.5603/OCP.2019.0005
·
Oncol Clin Pract 2019;15(1).

open access

Vol 15, No 1 (2019)
CASE REPORT
Published online: 2019-04-16

Abstract

A 54-year-old obese woman with a history of spina bifida was admitted to the hospital with malaise and fever accompanied by leucocytosis, thrombocytosis, and hypercalcaemia. As treatment for neurogenic bladder dysfunction she had a suprapubic catheter. Diagnostic workup for osteomyelitis revealed an unknown mass originating from the urinary bladder on MRI of the pelvis. Further diagnostic analyses showed that the mass was a squamous-cell carcinoma (SCC) with laboratory abnormalities as paraneoplastic phenomena mediated by PTH-related peptide and cytokines released by the SCC. Despite radiotherapy the patient died within two months after initial diagnosis. Squamous-cell carcinoma of the bladder is rare in western countries. In unresectable or metastatic disease survival rates are low due to low responsiveness to standard chemotherapy. Concurrent chemoradiotherapy might be an alternative in unresectable or locally advanced disease; however, evidence to support this is lacking. The poor survival in these patients raises the question of whether high-risk groups for SCC of the bladder, like paraplegic patients or patient with neurogenic bladder dysfunction, should receive screening even though the ideal starting point and frequency are still unknown.  

Abstract

A 54-year-old obese woman with a history of spina bifida was admitted to the hospital with malaise and fever accompanied by leucocytosis, thrombocytosis, and hypercalcaemia. As treatment for neurogenic bladder dysfunction she had a suprapubic catheter. Diagnostic workup for osteomyelitis revealed an unknown mass originating from the urinary bladder on MRI of the pelvis. Further diagnostic analyses showed that the mass was a squamous-cell carcinoma (SCC) with laboratory abnormalities as paraneoplastic phenomena mediated by PTH-related peptide and cytokines released by the SCC. Despite radiotherapy the patient died within two months after initial diagnosis. Squamous-cell carcinoma of the bladder is rare in western countries. In unresectable or metastatic disease survival rates are low due to low responsiveness to standard chemotherapy. Concurrent chemoradiotherapy might be an alternative in unresectable or locally advanced disease; however, evidence to support this is lacking. The poor survival in these patients raises the question of whether high-risk groups for SCC of the bladder, like paraplegic patients or patient with neurogenic bladder dysfunction, should receive screening even though the ideal starting point and frequency are still unknown.  

Get Citation

Keywords

suprapubic catheter, squamous-cell carcinoma suprapubic tract, neoplastic phenomena

About this article
Title

A paraplegic patient with fever and leucocytosis: not always what it seems

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 1 (2019)

Article type

Case report

Published online

2019-04-16

DOI

10.5603/OCP.2019.0005

Bibliographic record

Oncol Clin Pract 2019;15(1).

Keywords

suprapubic catheter
squamous-cell carcinoma suprapubic tract
neoplastic phenomena

Authors

Ashley J.R. De Bie
Simon Körver
Erik Kersten
Jérôme M.H. Kisters
Henricus J.E.J. Vrijhof
Jeroen Willems

References (16)
  1. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004; 93(2): 216–220.
  2. Martin JW, Vernez SL, Lotan Y, et al. Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort. World J Urol. 2018 [Epub ahead of print].
  3. Martin JW, Carballido EM, Ahmed A, et al. Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab J Urol. 2016; 14(3): 183–191.
  4. Zahoor H, Elson P, Stephenson A, et al. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018; 16(2): e437–e442.
  5. Manley KV, Hubbard R, Swallow D, et al. Risk factors for development of primary bladder squamous cell carcinoma. The Annals of The Royal College of Surgeons of England. 2017; 99(2): 155–160.
  6. Block NL, Whitmore WF. Leukemoid reaction, thrombocytosis and hypercalcemia associated with bladder cancer. J Urol. 1973; 110(6): 660–663.
  7. Desai PG, Khan SA, Jayachandran S, et al. Paraneoplastic syndrome in squamous cell carcinoma of urinary bladder. Urology. 1987; 30(3): 262–264.
  8. Khawaja MR, Bradford CA, Azar JM. Paraneoplastic leukocytosis: an unusual manifestation of squamous cell carcinoma of the urinary bladder. Oncology (Williston Park). 2013; 27(12): 1297–1301.
  9. Kato T, Yasuda K, Iida H, et al. Trousseau's syndrome caused by bladder cancer producing granulocyte colony-stimulating factor and parathyroid hormone-related protein: A case report. Oncol Lett. 2016; 12(5): 4214–4218.
  10. ASANUMA N, HAGIWARA K, MATSUMOTO I, et al. PTHrP-producing Tumor: Squamous Cell Carcinoma of the Liver Accompanied by Humoral Hypercalcemia of Malignancy, Increased IL-6 and Leukocytosis. Internal Medicine. 2002; 41(5): 371–376.
  11. Takaoka S, Yamane Y, Nishiki M, et al. Primary Pulmonary Squamous Cell Carcinoma Associated with Elevated IL-6, Leukocytosis, Hypercalcemia, Phagocytosis, Reactive Lymphadenopathy and Glomerular Mesangial Cell Proliferation via the Production of PTH-rP and G-CSF. Internal Medicine. 2008; 47(4): 275–279.
  12. Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007; 69(2): 255–259.
  13. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031): 1909–1920.
  14. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11): 1483–1492.
  15. El Masri y WS, Patil S, Prasanna KV, et al. To cystoscope or not to cystoscope patients with traumatic spinal cord injuries managed with indwelling urethral or suprapubic catheters? That is the question! Spinal Cord. 2014; 52(1): 49–53.
  16. Sammer U, Walter M, Knüpfer SC, et al. Do We Need Surveillance Urethro-Cystoscopy in Patients with Neurogenic Lower Urinary Tract Dysfunction? PLoS One. 2015; 10(10): e0140970.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl